Beyondspring (NASDAQ:BYSI) received a $52.00 price objective from equities researchers at Maxim Group in a note issued to investors on Thursday. The firm currently has a “buy” rating on the stock. Maxim Group’s price target suggests a potential upside of 68.50% from the stock’s current price.

The analysts wrote, “BeyondSpring announced that Pliabulin has met its primary endpoint in the P2 portion of its global Phase 2/3 clinical trial (Study 105) for the prevention of CIN with docetaxel. In addition, the company announced that a p value of < 0.0001 from its ongoing Phase 3 NSCLC clinical trial (Study 103) was achieved from 138 patients on a secondary endpoint of grade 4 neutropenia, which demonstrates Plinabulin’s ability to reduce docetaxel CIN. Interim anti-cancer efficacy data from Study 103 is expected in mid-2018."”

A number of other research analysts have also issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Beyondspring in a research note on Monday, August 21st. Zacks Investment Research lowered shares of Beyondspring from a “hold” rating to a “sell” rating in a research note on Monday, November 13th. Finally, Seaport Global Securities assumed coverage on shares of Beyondspring in a research note on Tuesday, December 5th. They set a “buy” rating and a $56.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $54.50.

Shares of Beyondspring (NASDAQ BYSI) traded up $2.41 during trading on Thursday, hitting $30.86. 7,700 shares of the stock were exchanged, compared to its average volume of 5,434. Beyondspring has a twelve month low of $16.55 and a twelve month high of $48.49.

Beyondspring (NASDAQ:BYSI) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. research analysts predict that Beyondspring will post -4.43 EPS for the current year.

An institutional investor recently bought a new position in Beyondspring stock. Tanaka Capital Management Inc. purchased a new stake in Beyondspring Inc (NASDAQ:BYSI) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 21,322 shares of the company’s stock, valued at approximately $914,000. Beyondspring comprises 2.1% of Tanaka Capital Management Inc.’s investment portfolio, making the stock its 16th biggest position. Tanaka Capital Management Inc. owned approximately 0.10% of Beyondspring at the end of the most recent quarter. 1.22% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This article was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/14/beyondspring-bysi-receives-buy-rating-from-maxim-group.html.

Beyondspring Company Profile

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.